Formulation Formulation and Evaluation of Luliconazole nanosponge gel using Experimental design

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
Narender Malothu, Sadhana Noothi, Anka Rao Areti, Vishnu Pulavarthy
{"title":"Formulation Formulation and Evaluation of Luliconazole nanosponge gel using Experimental design","authors":"Narender Malothu, Sadhana Noothi, Anka Rao Areti, Vishnu Pulavarthy","doi":"10.22146/ijp.7692","DOIUrl":null,"url":null,"abstract":"Different approaches are being in the practice for the topical application of antifungal drugs, although in a few cases, they have been found less efficient because of their poor cutaneous availability and permeability. Luliconazole (LUL) is one of the antifungal medications that is being used for the treatment of various superficial infections. The poor permeability of LUL is regarded to be a factor for its reduced efficacy. Hence, the current study aimed to develop a nanosponge hydrogel that would improve dermal availability and permeability. A set of nanosponge formulations (L1-L18) were designed with the help of central composite design (Design Expert 13, state ease Inc., Minneapolis, MN, USA). L1-L18 was prepared by using the emulsion solvent evaporation technique. The nanosponges were characterized for drug-excipient compatibility (FTIR, P-XRD, and DSC), and particle size, polydispersibility index, zeta potential, entrapment efficiency (EE), and in vitro drug release; further optimized. The optimized nanosponge formulation (L18) was taken to produce six hydrogels (LF1-LF6) of LUL by varied proportions of the gelling agent. In this process, initially, the gel was constituted with Carbopol 934/ sodium CMC/HPMC. Later, attained hydrogel texture was evaluated for its viscosity, swelling, and membrane permeability, followed by in vitro drug release, and antifungal efficacy study. The nanosponge formulations (L1-L17) had an average particle size of 109±0.45 to 386±0.34 nm, entrapment efficiency of 35.45±0.46- 89.65±0.37 % with 84.67±0.54 -99.65±0.48 % of drug release for 8 h. The formulation L18 was predicted with better responses in particle size, EE, and drug release i.e., 378±0.25 nm, 84.65±0.45%, and of 96.18±0.54%, respectively for 8 h. Out of six formulated nanosponge gels (LF1-LF6), LF2 showed an optimal viscosity (25.69 ±0.45 pa.S), pH (6.87±0.56) and % drug release (80.65 ±0.64%) in 8 h. Drug release was governed by non-fickian diffusion mechanisms and zero-order. Developed nanosponge hydrogel was found as stable and had a high rate of permeation with better retention which can be effective enough in topical applications.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INDONESIAN JOURNAL OF PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/ijp.7692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Different approaches are being in the practice for the topical application of antifungal drugs, although in a few cases, they have been found less efficient because of their poor cutaneous availability and permeability. Luliconazole (LUL) is one of the antifungal medications that is being used for the treatment of various superficial infections. The poor permeability of LUL is regarded to be a factor for its reduced efficacy. Hence, the current study aimed to develop a nanosponge hydrogel that would improve dermal availability and permeability. A set of nanosponge formulations (L1-L18) were designed with the help of central composite design (Design Expert 13, state ease Inc., Minneapolis, MN, USA). L1-L18 was prepared by using the emulsion solvent evaporation technique. The nanosponges were characterized for drug-excipient compatibility (FTIR, P-XRD, and DSC), and particle size, polydispersibility index, zeta potential, entrapment efficiency (EE), and in vitro drug release; further optimized. The optimized nanosponge formulation (L18) was taken to produce six hydrogels (LF1-LF6) of LUL by varied proportions of the gelling agent. In this process, initially, the gel was constituted with Carbopol 934/ sodium CMC/HPMC. Later, attained hydrogel texture was evaluated for its viscosity, swelling, and membrane permeability, followed by in vitro drug release, and antifungal efficacy study. The nanosponge formulations (L1-L17) had an average particle size of 109±0.45 to 386±0.34 nm, entrapment efficiency of 35.45±0.46- 89.65±0.37 % with 84.67±0.54 -99.65±0.48 % of drug release for 8 h. The formulation L18 was predicted with better responses in particle size, EE, and drug release i.e., 378±0.25 nm, 84.65±0.45%, and of 96.18±0.54%, respectively for 8 h. Out of six formulated nanosponge gels (LF1-LF6), LF2 showed an optimal viscosity (25.69 ±0.45 pa.S), pH (6.87±0.56) and % drug release (80.65 ±0.64%) in 8 h. Drug release was governed by non-fickian diffusion mechanisms and zero-order. Developed nanosponge hydrogel was found as stable and had a high rate of permeation with better retention which can be effective enough in topical applications.
采用实验设计制备露立康唑纳米海绵凝胶
局部应用抗真菌药物的实践中有不同的方法,尽管在少数情况下,由于它们的皮肤可用性和渗透性差,它们被发现效率较低。露立康唑(LUL)是一种抗真菌药物,被用于治疗各种表面感染。LUL的渗透性差被认为是其效能降低的一个因素。因此,目前的研究旨在开发一种纳米海绵水凝胶,以提高皮肤的可用性和渗透性。采用中心复合设计(design Expert 13, state ease Inc., Minneapolis, MN, USA)设计了一套纳米海绵配方(L1-L18)。采用乳液溶剂蒸发法制备L1-L18。采用FTIR、P-XRD和DSC对纳米海绵的药物与辅料相容性、粒径、多分散性指数、zeta电位、包封效率(EE)和体外药物释放度进行表征;进一步优化。采用优化后的纳米海绵配方(L18),通过不同配比的胶凝剂制备了6种LUL水凝胶(LF1-LF6)。在此过程中,最初以卡波波尔934/钠CMC/HPMC构成凝胶。随后,对获得的水凝胶结构进行粘度、肿胀和膜通透性评估,随后进行体外药物释放和抗真菌功效研究。纳米海绵凝胶(L1-L17)的平均粒径为109±0.45 ~ 386±0.34 nm,包封效率为35.45±0.46 ~ 89.65±0.37%,8 h释药率为84.67±0.54 ~ 99.65±0.48%。L18的粒径、EE和释药率分别为378±0.25 nm、84.65±0.45%和96.18±0.54%,8 h释药效果较好。在6种纳米海绵凝胶(LF1-LF6)中,LF2的最佳黏度为25.69±0.45 pa.S;8 h内pH值为6.87±0.56,释药率为80.65±0.64%。药物释放受非粘性扩散机制控制,为零级释药。制备的纳米海绵水凝胶具有稳定性好、渗透率高、保持性好等特点,可以有效地局部应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
INDONESIAN JOURNAL OF PHARMACY
INDONESIAN JOURNAL OF PHARMACY PHARMACOLOGY & PHARMACY-
CiteScore
1.20
自引率
0.00%
发文量
38
审稿时长
12 weeks
期刊介绍: The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信